Vera Therapeutics, Inc.

NasdaqGM:VERA Stock Report

Market Cap: US$2.7b

Vera Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

Vera Therapeutics has a total shareholder equity of $289.1M and total debt of $50.5M, which brings its debt-to-equity ratio to 17.5%. Its total assets and total liabilities are $368.6M and $79.5M respectively.

Key information

17.5%

Debt to equity ratio

US$50.47m

Debt

Interest coverage ration/a
CashUS$353.31m
EquityUS$289.06m
Total liabilitiesUS$79.50m
Total assetsUS$368.56m

Recent financial health updates

Recent updates

Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late

Dec 22

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Oct 07
Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 04

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Jul 22

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Jul 05
Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Jan 25

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Sep 06

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Aug 10

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16
Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25
We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

Financial Position Analysis

Short Term Liabilities: VERA's short term assets ($364.1M) exceed its short term liabilities ($26.5M).

Long Term Liabilities: VERA's short term assets ($364.1M) exceed its long term liabilities ($53.0M).


Debt to Equity History and Analysis

Debt Level: VERA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if VERA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VERA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VERA has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 35.9% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:07
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vera Therapeutics, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pete StavropoulosCantor Fitzgerald & Co.
Liisa BaykoEvercore ISI
Vamil DivanGuggenheim Securities, LLC